At the top of Monday’s biggest winners in healthcare, Aspect Medical Systems, Inc. (NASDAQ:ASPM). It was announced that Covidien (NYSE:COV) plans to buy the brain monitor maker for about $210 million, giving the medical products company an expanded presence in the operating room.

"Aspect's (technology) is recognized as the market leader but did not have the marketing or distribution muscle which Covidien can provide," said Jefferies analyst Peter Bye.

Covidien announced that they would pay $12 in cash for each share of Aspect, a premium of about 56 percent over the stock's Friday close of $7.67 so shares closed the day 55% higher at $11.96 +4.29 and were trading a bit higher after hours.

There was some very strange trading action on I-Flow Corporation (NASDAQ:IFLO), who announced last week the availability of its family of four conveniently sized ON-Q® SilverDressings™- which are thin film dressings containing ionic silver that is 99.99 percent effective in killing or inhibiting the growth of a wide range of microorganisms including MRSA1, for up to 7 days. This added layer of antimicrobial protection may reduce the risk of infection, which would help facilities avoid incremental treatment costs.  The CDC reports that there are nearly 375,000 surgical site infections in the U.S. each year. The stock ended the day up 16% at $12.14 +1.70 then in after hours trading, the stock gave up most of its gains falling to 11.09 -1.05 (-8.65%). It will be interesting to see what happens to this stock tomorrow morning.

Shares of Novavax, Inc.(NASDAQ:NVAX), whose vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology is attempting to rebound after their recent skid. On Sept 16, the vaccine maker said it planned to raise capital by selling a total of $10 million in gross proceeds of its common shares. Today it looks like they finally broke out of that downward pattern. Shares closed the day at $4.41 +0.61 (up 16.05%).

Apparently our readers “Took advantage of the BioDelivery Dip” and gobbled up shares of BioDelivery Sciences International (NASDAQ:BDSI). The stock was way oversold and as BioMedReport's Vinny Cassano reported yesterday morning, milestone payments due to the company alone equal nearly a third of the current market cap, this without taking into consideration either the potential of the pipeline nor the possibility of the company's cancer pain drug Onsolis reaching the sales thresholds that would garner the additional thirty million dollar payment. Informed investors bought shares and the stock closed up nearly 13% at $4.79 +.55

Here is a look at the rest of Monday's Healthcare winners and losers:

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

---

Add this page to your favorite Social Bookmarking websites

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed

Name

Email

Comment

smaller | bigger

Subscribe via email (registered users only)

Add Comment Preview